Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
… type EGFR and patients with EGFR mutations respectively. In either groups of wild-type EGFR
or mutant EGFR, gefitinib and erlotinib did … Erlotinib and gefitinib treatments do not result in …
or mutant EGFR, gefitinib and erlotinib did … Erlotinib and gefitinib treatments do not result in …
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
… To the best of our knowledge, this is the first study worldwide to compare the efficacy of
erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …
erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao, V Miller, M Zakowski… - Proceedings of the …, 2004 - National Acad Sciences
… EGFR mutations with sensitivity to the TKI, gefitinib (17, 18). … inhibitor, erlotinib, contain
similar types of EGFR mutations. … taking gefitinib or erlotinib contain mutations in the EGFR TK …
similar types of EGFR mutations. … taking gefitinib or erlotinib contain mutations in the EGFR TK …
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
DB Costa, KSH Nguyen, BC Cho, LV Sequist… - Clinical cancer …, 2008 - AACR
… Other secondary mutations (D761Y and L747S) are rare. Our goal was to … of erlotinib 150
mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib …
mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib …
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
CK Lee, L Davies, YL Wu, T Mitsudomi… - JNCI: Journal of the …, 2017 - academic.oup.com
… of uncommon EGFR mutations (13). This question cannot be addressed in this meta-analysis …
gefitinib and erlotinib as most of the included RCTs excluded uncommon EGFR mutations. …
gefitinib and erlotinib as most of the included RCTs excluded uncommon EGFR mutations. …
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
… gefitinib or erlotinib display additional mutations in the EGFR kinase domain, we have examined
the status of EGFR … In all three patients, we found EGFR mutations associated with drug …
the status of EGFR … In all three patients, we found EGFR mutations associated with drug …
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen… - British journal of …, 2017 - nature.com
… receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression
or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib …
or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib …
… Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
S Heon, BY Yeap, NI Lindeman, VA Joshi… - Clinical Cancer …, 2012 - AACR
… If validated, our findings suggest that gefitinib and erlotinib may be effective at delaying
and/or preventing CNS metastases from NSCLC in patients with sensitizing EGFR mutations. As …
and/or preventing CNS metastases from NSCLC in patients with sensitizing EGFR mutations. As …
… of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
… Patient age and EGFR mutation genotype were significant … EGFR mutations initially treated
with gefitinib or erlotinib than … without EGFR mutations and the impact of gefitinib and erlotinib …
with gefitinib or erlotinib than … without EGFR mutations and the impact of gefitinib and erlotinib …
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
T Mitsudomi - The Lancet Oncology, 2011 - thelancet.com
… shows the importance of EGFR mutation testing and patient selection according to these test
results for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months …
results for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months …
相关搜索
- cell lung cancer egfr mutations
- egfr mutation status
- efficacy of gefitinib egfr mutations
- pooled analysis egfr mutations
- gefitinib and erlotinib in patients
- lung adenocarcinomas gefitinib or erlotinib
- erlotinib in advanced nsclc egfr mutations
- gefitinib therapy egfr mutations
- effectiveness of erlotinib egfr gene mutations
- deletion mutations gefitinib or erlotinib
- non-adenocarcinoma nsclc patients with egfr mutation
- active egfr mutation
- gefitinib and erlotinib sensitivity of tumors
- brain metastases egfr mutations
- clinical outcomes egfr mutations
- somatic egfr mutations gefitinib or erlotinib